Login to Your Account



Pharma: Other News To Note


Wednesday, September 12, 2012

• Pfizer Inc., of New York, said the World Health Organization granted an expansion to the prequalification of Pfizer's pneumococcal conjugate vaccine, Prevenar 13 (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]), to include adults 50 and older against pneumonia and invasive disease caused by the 13 pneumococcal serotypes in the vaccine.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription